Immutep Ltd (PRRUF) — 6-K Filings

6-K Filings (50)

• Immutep Ltd. Files Routine 6-K Report — Dec 23, 2025 Risk: low
  Immutep Ltd. filed a Form 6-K on December 23, 2025, reporting its status as a foreign private issuer. The company, previously known as Prima BioMed Ltd, is inco
• Immutep Ltd Files Routine 6-K Report — Dec 17, 2025 Risk: low
  Immutep Limited filed a Form 6-K on December 17, 2025, reporting as of December 16, 2025. The company, formerly known as Prima BioMed Ltd, is a pharmaceutical p
• 6-K Filing — Dec 9, 2025
• 6-K Filing — Dec 3, 2025
• 6-K Filing — Nov 14, 2025
• IMMUTEP Ltd Files Form 6-K — Nov 4, 2025 Risk: low
  On November 3, 2025, IMMUTEP Ltd filed a Form 6-K. The company, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia, and operates in the p
• Immutep Ltd. Files Routine 6-K Disclosure — Oct 30, 2025 Risk: low
  Immutep Ltd. (NASDAQ: IMMP) filed a Form 6-K on October 30, 2025, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed
• Immutep Ltd Files Routine 6-K Disclosure — Oct 21, 2025 Risk: low
  Immutep Ltd filed a Form 6-K on October 21, 2025, reporting as a foreign private issuer. The company, previously known as Prima BioMed Ltd, is based in Sydney,
• Immutep Ltd Files Routine 6-K Disclosure — Oct 14, 2025 Risk: low
  Immutep Limited filed a Form 6-K on October 13, 2025, reporting as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is based in Sydney
• IMMUTEP Ltd Files Form 6-K — Oct 9, 2025 Risk: low
  On October 9, 2025, IMMUTEP Ltd filed a Form 6-K. The company, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia, and operates in the Ph
• IMMUTEP Ltd Files Form 6-K — Sep 23, 2025 Risk: low
  On September 22, 2025, IMMUTEP Ltd filed a Form 6-K. The company, formerly known as Prima BioMed Ltd, is based in Sydney, Australia, and operates in the Pharmac
• Immutep Ltd. Files Routine 6-K Disclosure — Sep 3, 2025 Risk: low
  Immutep Ltd. filed a Form 6-K on August 29, 2025, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is based in
• Immutep Ltd Files Routine 6-K Report — Aug 7, 2025 Risk: low
  Immutep Limited filed a Form 6-K on August 7, 2025, reporting information as of August 5, 2025. The company, formerly known as Prima BioMed Ltd, is based in Syd
• Immutep Ltd Files Routine 6-K Disclosure — Jul 31, 2025 Risk: low
  Immutep Limited filed a Form 6-K on July 30, 2025, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is based i
• Immutep Ltd Files Routine 6-K Report — Jun 24, 2025 Risk: low
  Immutep Limited filed a Form 6-K on June 24, 2025, reporting as a foreign private issuer. The company, previously known as Prima BioMed Ltd, is based in Sydney,
• Immutep Ltd. Files SEC Form 6-K — May 28, 2025 Risk: low
  Immutep Ltd. announced on May 26, 2025, that it has submitted a Form 6-K to the SEC. This filing is a report of a foreign private issuer and does not contain sp
• IMMUTEP Ltd Files Form 6-K — May 16, 2025 Risk: low
  On May 15, 2025, IMMUTEP Limited filed a Form 6-K. The company, formerly known as Prima BioMed Ltd, is based in Sydney, Australia, and operates in the pharmaceu
• Immutep Ltd Files Routine 6-K Report — May 6, 2025 Risk: low
  Immutep Limited filed a Form 6-K on May 5, 2025, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is incorpora
• Immutep Ltd Files Routine 6-K Report — Apr 30, 2025 Risk: low
  Immutep Limited filed a Form 6-K on April 29, 2025, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is based
• IMMUTEP Ltd Files Form 6-K — Mar 26, 2025 Risk: low
  On March 25, 2025, IMMUTEP Limited filed a Form 6-K. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and operates in the pharmac
• IMMUTEP Ltd Files Form 6-K — Feb 27, 2025 Risk: low
  On February 26, 2025, IMMUTEP Ltd filed a Form 6-K. The company, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia, and operates in the
• Immutep Ltd Files Form 6-K — Feb 3, 2025 Risk: low
  Immutep Limited filed a Form 6-K on February 3, 2025, reporting information as of January 31, 2025. The company, previously known as Prima BioMed Ltd, is incorp
• Immutep Ltd Files Form 6-K — Dec 17, 2024 Risk: low
  Immutep Limited, formerly Prima BioMed Ltd, filed a Form 6-K on December 17, 2024. The company, based in Sydney, Australia, operates in the Pharmaceutical Prepa
• Immutep Ltd. Files Routine 6-K Report — Dec 12, 2024 Risk: low
  Immutep Ltd. filed a Form 6-K on December 12, 2024, reporting as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is incorporated in A
• Immutep Ltd Files 6-K Report — Dec 10, 2024 Risk: low
  Immutep Limited filed a Form 6-K on December 10, 2024. The filing is a report of a foreign private issuer and indicates that the company files annual reports un
• Immutep Ltd Files 6-K Report — Nov 15, 2024 Risk: low
  Immutep Limited filed a Form 6-K on November 15, 2024, reporting its status as a foreign private issuer. The company, previously known as Prima BioMed Ltd, is i
• Immutep Ltd Files Routine 6-K Report — Oct 30, 2024 Risk: low
  Immutep Limited filed a Form 6-K on October 29, 2024, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is inco
• IMMUTEP Ltd Files Form 6-K — Oct 3, 2024 Risk: low
  On October 3, 2024, IMMUTEP Ltd filed a Form 6-K. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and operates in the pharmaceut
• Immutep Ltd. Files SEC Form 6-K — Sep 24, 2024 Risk: low
  Immutep Ltd. announced on September 24, 2024, that it has filed a Form 6-K with the SEC. This filing is a report of a foreign private issuer and does not contai
• IMMUTEP Ltd Files Form 6-K — Sep 17, 2024 Risk: low
  On September 16, 2024, IMMUTEP Limited filed a Form 6-K. The company, formerly known as Prima BioMed Ltd, is based in Sydney, Australia, and operates in the Pha
• Immutep Ltd Files 6-K, Confirms Sydney HQ — Sep 10, 2024 Risk: low
  Immutep Limited filed a Form 6-K on September 9, 2024, reporting its status as a foreign private issuer. The filing confirms its principal executive office is l
• Immutep Ltd Files Form 6-K — Sep 3, 2024 Risk: low
  Immutep Limited filed a Form 6-K on September 3, 2024, reporting information as of August 30, 2024. The company, formerly known as Prima BioMed Ltd, is based in
• IMMUTEP Ltd Files Form 6-K — Aug 21, 2024 Risk: low
  On August 20, 2024, IMMUTEP Ltd filed a Form 6-K. The filing indicates that the company, previously known as Prima BioMed Ltd until November 19, 2010, is a fore
• Immutep Ltd. Files SEC Form 6-K — Aug 15, 2024 Risk: low
  Immutep Ltd. announced on August 14, 2024, that it has filed a Form 6-K with the SEC. This filing is a report of a foreign private issuer and does not contain n
• Immutep Ltd. Files 20-F Annual Report — Aug 1, 2024 Risk: low
  Immutep Ltd. announced on July 31, 2024, that it has filed its annual report on Form 20-F. The company, previously known as Prima BioMed Ltd, is incorporated in
• Immutep Partners with Merck for Efti Combination Trials — Jul 23, 2024 Risk: medium
  Immutep Ltd. announced on July 22, 2024, that it has entered into a clinical supply agreement with Merck & Co. for its lead product candidate, eftilagimod alpha
• IMMUTEP Ltd Files Form 6-K — Jul 17, 2024 Risk: low
  On July 17, 2024, IMMUTEP Ltd filed a Form 6-K. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and operates in the Pharmaceutic
• Immutep Acquires SymbioCelltics to Boost Cancer Drug Development — Jul 15, 2024 Risk: medium
  Immutep Ltd. announced on July 12, 2024, that it has entered into a binding agreement to acquire all outstanding shares of SymbioCelltics Pty Ltd. This acquisit
• IMMUTEP Ltd Files Form 6-K — Jul 3, 2024 Risk: low
  On July 3, 2024, IMMUTEP Ltd filed a Form 6-K. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and operates in the Pharmaceutica
• Immutep Ltd Files 6-K Report — Jun 28, 2024 Risk: low
  Immutep Limited filed a Form 6-K on June 28, 2024, reporting information as of June 27, 2024. The company, previously known as Prima BioMed Ltd, is incorporated
• IMMUTEP Ltd Files Routine 6-K Report — Jun 25, 2024 Risk: low
  On June 24, 2024, IMMUTEP Ltd filed a Form 6-K, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is based in S
• Immutep Ltd. Files SEC Form 6-K — Jun 6, 2024 Risk: low
  Immutep Ltd. announced on June 5, 2024, that it has filed a Form 6-K with the SEC. This filing is a report of a foreign private issuer and does not contain spec
• Immutep Ltd Files Routine 6-K Disclosure — Jun 4, 2024 Risk: low
  Immutep Limited filed a Form 6-K on June 4, 2024, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is incorpor
• IMMUTEP Ltd Files Form 6-K — May 16, 2024 Risk: low
  On May 15, 2024, IMMUTEP Ltd filed a Form 6-K. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and operates in the pharmaceutica
• IMMUTEP Ltd Files Form 6-K — May 3, 2024 Risk: low
  On May 2, 2024, IMMUTEP Limited filed a Form 6-K. The company, previously known as Prima BioMed Ltd, is incorporated in Australia and operates in the Pharmaceut
• Immutep Ltd Files Form 6-K — Apr 30, 2024 Risk: low
  Immutep Limited filed a Form 6-K on April 29, 2024, reporting its status as a foreign private issuer. The company, formerly known as Prima BioMed Ltd, is incorp
• IMMUTEP Ltd Files Form 6-K Report — Apr 25, 2024 Risk: low
  On April 24, 2024, IMMUTEP Limited filed a Form 6-K. The filing is a report of a foreign private issuer and does not contain specific financial figures or opera
• Immutep Ltd Files Form 6-K — Apr 19, 2024 Risk: low
  Immutep Limited filed a Form 6-K on April 19, 2024, reporting information as of April 18, 2024. The company, previously known as Prima BioMed Ltd, is incorporat
• Immutep Ltd Files 6-K, Confirms Sydney HQ — Mar 6, 2024 Risk: low
  Immutep Limited filed a Form 6-K on March 5, 2024, reporting its status as a foreign private issuer. The filing confirms the company's principal executive offic
• Immutep Files 6-K, Confirms 20-F Annual Reporting — Feb 29, 2024 Risk: low
  Immutep Ltd, a foreign private issuer, filed a Form 6-K with the SEC on February 29, 2024, for the period ending February 28, 2024. The company, previously know

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX